Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial:

Hyun Sook Kim,Won-Ho Choi,Bo-Young Kim,Sung-Soo Kim,Sang-Il Lee,Sang-Hyon Kim,Sung Jae Choi,Geun Tae Kim,Jin Wuk Hur,Myeung-Su Lee,Yun-Sung Kim,Seung-Jae Hong

Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial:

2020

Hyun Sook Kim
Won-Ho Choi
Bo-Young Kim
Sung-Soo Kim
Sang-Il Lee
Sang-Hyon Kim
Sung Jae Choi
Geun Tae Kim
Jin Wuk Hur
Myeung-Su Lee
Yun-Sung Kim
Seung-Jae Hong

ObjectivesCelecoxib is a selective cyclooxygenase (COX)-2 inhibitor that is commonly used to reduce the incidence of gastrointestinal (GI) complications in patients with rheumatoid arthritis (RA). ...

Keywords:

Clinical trial
Anesthesia
Diabetes mellitus
non inferiority
Cyclooxygenase
Medicine
in patient
Rheumatoid arthritis
pain relief
double blind
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations